Abstract: This invention relates to methods of treating sexual dysfunction and/or maintaining sexual function in a patient by administering to the patient neuroactive steroids.

Abstract: This invention relates to methods of treating sexual dysfunction and/or maintaining sexual function in a patient by administering to the patient neuroactive steroids.

Abstract: This disclosure relates to Compound 1, pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof, for the treatment of CNS related disorders, e.g., tremor, e.g., essential tremor; depression; and anxiety disorder, and methods for improving the effectiveness of the administration of Compound 1 for treating said CNS related disorders. The disclosure also relates to methods of increasing the bioavailability of a Compound 1 or pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof.

Abstract: Provided herein are methods for treating depression, such as major depressive disorder, in a subject in need thereof, comprising administering to the subject an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are methods for treating depression, such as postpartum depression or major depressive disorder, in a subject in need thereof, comprising administering to the subject an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof:

Abstract: Provided herein are methods for treating depression, such as postpartum depression or major depressive disorder, in a subject in need thereof, comprising administering to the subject an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof: (Compound I).

Abstract: This disclosure relates to Compound (I), pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof, for the treatment of CNS related disorders, e.g., tremor, e.g., essential tremor; depression; and anxiety disorder, and methods for improving the effectiveness of the administration of Compound 1 for treating said CNS related disorders. The disclosure also relates to methods of increasing the bioavailability of a Compound 1 or pharmaceutically acceptable salts, or pharmaceutically acceptable compositions thereof.

Abstract: Provided herein are methods for treating depression, such as postpartum depression or major depressive disorder, in a subject in need thereof, comprising administering to the subject an effective amount of Compound 1 or a pharmaceutically acceptable salt thereof:

Abstract: The invention relates to methods that can detect the abnormal function of the N-methyl-D-aspartate (NMDA) receptor, which can ascertain whether an individual has vulnerability for schizophrenia or depression. The invention relates to measuring blood plasma osmolality and the concentration of least one biomarker in conjunction with hypertonic solution infusion as a method for detecting or diagnosing schizophrenia or depression. The invention further relates to using arginine-vasopressin (AVP), neurophysin II, and copeptin as biomarkers in a method for detecting or diagnosing schizophrenia or depression.